Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

[Image: see text] Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite d-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH mutation. Herein, we describe...

詳細記述

保存先:
書誌詳細
出版年:ACS Med Chem Lett
主要な著者: Konteatis, Zenon, Artin, Erin, Nicolay, Brandon, Straley, Kimberly, Padyana, Anil K., Jin, Lei, Chen, Yue, Narayaraswamy, Rohini, Tong, Shuilong, Wang, Feng, Zhou, Ding, Cui, Dawei, Cai, Zhenwei, Luo, Zhiyong, Fang, Cheng, Tang, Huachun, Lv, Xiaobing, Nagaraja, Raj, Yang, Hua, Su, Shin-San M., Sui, Zhihua, Dang, Lenny, Yen, Katharine, Popovici-Muller, Janeta, Codega, Paolo, Campos, Carl, Mellinghoff, Ingo K., Biller, Scott A.
フォーマット: Artigo
言語:Inglês
出版事項: American Chemical Society 2020
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7025383/
https://ncbi.nlm.nih.gov/pubmed/32071674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00509
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料